Routine Endoscopic Surveillance is NOT Recommended for Mild Intestinal Metaplasia
For patients with mild (non-dysplastic) intestinal metaplasia limited to the antrum without additional risk factors, routine endoscopic surveillance is not recommended. 1
Key Management Principles
The 2020 AGA guidelines make a conditional recommendation against routine endoscopic surveillance for gastric intestinal metaplasia (GIM), based on very low-quality evidence 1. This represents the most authoritative US guidance and aligns with the principle that most patients with limited GIM do not require ongoing endoscopy.
When Surveillance Can Be Avoided
No surveillance is needed for patients with:
- Mild to moderate intestinal metaplasia restricted to the antrum only
- No family history of gastric cancer
- Complete (not incomplete) intestinal metaplasia
- Successfully eradicated H. pylori infection
- No extensive disease (not involving both antrum and body)
The 2019 ESGE guidelines explicitly state that "for patients with mild to moderate atrophy restricted to the antrum there is no evidence to recommend surveillance" 3, and the 2020 ESGE position statement recommends against surveillance of those with intestinal metaplasia limited to the antrum unless additional risk factors are present 2.
When Surveillance Should Be Considered (3-5 Year Intervals)
Through shared decision-making, surveillance may be reasonable for patients who have ANY of these higher-risk features:
GIM-specific risk factors:
- Incomplete (Type III) intestinal metaplasia rather than complete type
- Extensive GIM involving both antrum AND body (not just antrum alone)
- Family history of gastric cancer in a first-degree relative
Patient demographic risk factors:
- Racial/ethnic minorities (particularly Asian, Hispanic, Black populations)
- Immigrants from high gastric cancer incidence regions (East Asia, Eastern Europe, Central/South America)
If surveillance is elected after shared decision-making, the recommended interval is every 3-5 years per AGA guidelines 1. The more recent 2025 ESGE update recommends a 3-year interval specifically for extensive disease 4, while the 2025 ACG guideline also supports 3-year intervals for high-risk patients 5.
Critical Action: Test and Eradicate H. pylori
All patients with GIM must be tested for H. pylori and receive eradication therapy if positive - this is a strong recommendation with moderate-quality evidence 1. This is the single most important intervention, as eradication may prevent progression and reduces gastric cancer risk 1, 4, 3.
Common Pitfalls to Avoid
Don't automatically schedule surveillance endoscopy just because the pathology report mentions "intestinal metaplasia" - most cases are mild and antrum-limited, requiring no surveillance
Don't order repeat endoscopy within 1 year for risk stratification unless there are concerns about the completeness of the baseline endoscopy or the patient has multiple high-risk features 1
Don't continue surveillance in patients over age 80 or those with less than 10 years life expectancy 4, 2
Ensure proper baseline endoscopy was performed - high-quality examination with biopsies from at least 2 sites (antrum and corpus) in separate vials is essential for accurate risk stratification 4, 3
The Bottom Line Algorithm
For mild intestinal metaplasia:
- Test and eradicate H. pylori (mandatory)
- Assess extent: Limited to antrum only? → Likely no surveillance needed
- Check for risk factors: Family history? Incomplete type? Immigrant from high-risk region?
- If NO risk factors → No surveillance, reassure patient
- If risk factors present → Discuss surveillance via shared decision-making; if elected, perform every 3-5 years with high-quality endoscopy
The evidence consistently shows that the vast majority of patients with mild, antrum-limited GIM without additional risk factors do not benefit from routine surveillance endoscopy 1, 2.